WETH - WETH

La cadena de opciones muestra datos clave de las opciones de acciones de Wetouch Technology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Wetouch Technology..

Wetouch Technology (NASDAQ:WETH) Bolsa, Cadena de Opciones

Wetouch Technology

Wetouch Technology Inc is a touch panel supplier focused on R & D, production and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots and charging stations. The company sells touchscreen products both domestically in China and internationally, covering the majority of areas in China, Taiwan, South Korea, and Germany.

Wetouch Technology Inc

J.D. WEATHERSPOON PLC by J.D. Wetherspoon PLC

Wetherspoon (J D) PLC

J.D. WETHERSPOON S/ADR by J.D. Wetherspoon PLC

Coya is on track and plans to submit the IND for COYA 302 (a proprietary combination of the low dose-rhIL-2 + CTLA4-Ig) by the end of June supporting the initiation of the Phase 2b study in patients with ALS
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.coyatherapeutics.com&amp;esheet=54263067&amp;newsitemid=20250602775188&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=dd0a5b2c88a4afdcc6c1ab9865fe6f62">Coya Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) ("Coya") today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin). Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intellectual property spanning multiple indications both as monotherapy and combination therapies.

News

COYA

Coya Therapeutics Announces Issuance Of U.S. Patent Relevant To Investigational RTU Liquid Formulation Of IL-2

Jefferies analyst Stephanie Moore upgrades Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) from Hold to Buy and raises the price target from $55 to $65.

Upgrades

Price Target

Analyst Ratings

Jefferies Upgrades Rollins to Buy, Raises Price Target to $65

Goldman Sachs analyst David Roman initiated coverage on three companies, explaining that diabetes technology, including insulin pumps and continuous glucose monitors (CGMs), is expected to grow at a <a href="https://www.benzinga.com/topic/diabetes">strong double-digit pace</a>.
<h3 class="wp-block-heading">Insulet</h3>
Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), citing the company to benefit from accelerating the adoption of patch pump technology as it is the only participant in the category currently.
Goldman Sachs initiated Insulet on Thursday with a Buy rating and <a href="https://www.benzinga.com/quote/PODD/analyst-ratings" target="_blank" rel="noreferrer noopener">a price target of $380</a>. The analyst highlights the company&#8217;s pipeline, which can potentially strengthen its relative position. Sustained top-line growth should support outsized adjusted EBITDA results and yield meaningful upside over the next several years.
Analyst David Roman writes, &#8220;We expect Omnipod's superior form factor and relative differentiation as a result to be the key contributor to Insulet's share capture as the insulin pump market moves into its next leg of adoption. In our view, the company is best positioned for the opportunities ahead in insulin delivery growth.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44745766/fda-approves-dexcoms-15-day-wearable-glucose-management-system-us-launch-planned-in-second-half-of-2025" rel="noreferrer noopener">FDA Approves Dexcom&#8217;s 15-Day Wearable Glucose Management System. Company Plans US Launch</a>
<h3 class="wp-block-heading">Dexcom</h3>
Goldman Sachs initiated DexCom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">price target of $104</a>, supported by a constructive view of the company&#8217;s technology and long-term opportunity set.
Roman adds the potential upside from consumer-related adoption and strong P&amp;L leverage, which should continue through the balance of 2025.
&#8220;Taking all patient cohorts into consideration, we expect Dexcom to remain ahead in the established Type 1 and Type 2 MDI segments. And in the higher growth T2 Basal and non-insulin populations, we expect Dexcom will take some patient share from Abbott over the intermediate term, off a much lower relative base&#8230;&#8221;
The CGM market is still mainly a two-player race between Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) and DexCom, Roman says.
However, the pump market is becoming more crowded, with more companies entering and customer needs changing. Hence, Goldman Sachs reiterated Abbott as a Buy and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) as Neutral.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45321429/insulet-posts-strong-q1-results-raises-forecasts-on-momentum-in-us-and-abroad" rel="noreferrer noopener">Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad</a>
<h3 class="wp-block-heading">Beta Bionics</h3>
Goldman Sachs initiated coverage on newly listed Beta Bionics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>). The diabetes management solutions provider closed its upsized IPO of 13.8 million at $17&nbsp;per share in January, raising approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43415288/beta-bionics-announces-closing-of-234-6-million-initial-public-offering-and-full-exercise-of-under" rel="noreferrer noopener">$212.1 million in gross proceeds</a>.
The analyst initiated a Neutral rating and a <a href="https://www.benzinga.com/quote/BBNX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $16</a>, noting the company's iLet technology is well-suited for a targeted segment of the Type 1 market.
<ul class="wp-block-list">
<li>iLet is still in the early adoption phase, so its short-term growth is expected to be stronger than that of other diabetes-related companies and similar-sized medical technology firms.</li>
<li>Also, market estimates mostly reflect the growth potential over the next few years. The stock's valuation also seems to factor in this expected growth and the likelihood that the company will need to raise more money to reach break-even cash flow.</li>
</ul>
Price Action: PODD stock is up 0.14% at $324.31, BBNX stock is up 10% at $16.90, and DXCM stock is up 1% at $85.71 at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/05/45693375/summit-therapeutics-closely-watched-lung-cancer-study-of-ivonescimab-misses-overall-survival-endpoint" target="_blank" rel="noreferrer noopener">Summit Therapeutics&#8217; Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Health Care

Initiation

General

BBNX

DXCM

PODD

TNDM

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

General Mills And Lactalis Receive Regulatory Clearance For Sale OF U.S. Yogurt Transaction

WIIM

LYRA

Lyra Therapeutics shares are trading higher after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers
Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25
SYDNEY, Australia, June 02, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that preclinical data from studies with the Lu177-B7H3-monoclonal antibody RV01 demonstrated favourable biodistribution and showed that RV01 maintained high tumour uptake. In addition, the Fc region modifications of the monoclonal antibody (mAb) confirm a shorter half-life, compared to traditional mAbs. The shorter half-life and other Fc modifications have the potential to limit off-target exposure to the isotope and mitigate toxicities associated with traditional monoclonal antibody therapies.
RV01 is the Company's B7-H3-targeted radiopharmaceutical therapy designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumours and not in healthy tissues, which is being developed in partnership with MD Anderson Cancer Center. The B7-H3 targeting monoclonal antibody (mAb) is designed to target various solid tumours that express the B7-H3 protein. High expression of this target is associated with a poor prognosis in many cancer types.
The new preclinical data corroborate conclusions from earlier preclinical mouse studies that identified a high-affinity antibody highly selective to the cancer-specific 4Ig isoform of the B7-H3 receptor, demonstrated complete regression of established solid tumours with treatment and showed promising evidence of immune system stimulation and the ability to confer immune memory.

RADX

Radiopharm Theranostics Says Preclinical Data From Studies With Lu177-B7H3-Monoclonal Antibody RV01 Demonstrates Favourable Biodistribution And Shows That RV01 Maintained High Tumour Uptake

Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract
HPV16-positive is the most rapidly increasing HNSCC in the US
VERSATILE-003 is the only ongoing Phase 3 clinical trial exclusively addressing 1L r/m HPV16-positive HNSCC
PRINCETON, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced publication of three Versamune&#xAE; HPV abstracts now available on the <a href="https://www.globenewswire.com/Tracker?data=ctgYUManXlUn9vXDbbZMFFqOJNNi_BKXlsy4YjYWF17J55joStlSKwaXSle3O56ubhP0psmiNueusD5j7EeKEz3qWOn54wF68KQCvF5_11ktrVp610uqjaxVY9otO537jxXOPBw4I1fUSbPzSa2eTQJTmWeP4HebVUhM-_Hj_iU=">2025 American Society of Clinical Oncology (ASCO) Annual Meeting</a> website. These abstracts summarize Versamune&#xAE; HPV (PDS0101) studies that were presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois.
It is estimated that over 50% of head and neck squamous cell carcinoma (HNSCC) cases in the US are HPV16-positive.1 HPV-positive and HPV-negative HNSCC are two distinct diseases with different underlying causes, origin, risk factors, and contributions to the development of HNSCC. Multiple types of HPV are associated with HSNCC, and those cases are commonly identified with a p16 histochemistry test and referred to as p16-positive. A p16-positive test result suggests that the patient's cancer may be due to any of the over 100 types of HPV. PDS Biotech is specifically addressing HNSCC related to HPV type 16 (HPV16), the most carcinogenic type of HPV. 2 HPV16-positive HNSCC has been identified as a rapidly growing and severe medical need.3,4 HPV16 is a specific type of HPV that must be confirmed using a polymerase chain reaction (PCR) test.

Biotech

PDSB

PDS Biotech Reports Durable 30-Month Median Overall Survival In 1L Recurrent/Metastatic HNSCC, Highlights Urgent Need In Rapidly Rising HPV16-Positive Cases

<ul>
<li>Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo &nbsp;</li>
<li>Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies &nbsp;</li>
<li>Safety profile consistent with previous studies, with no new safety signals identified&nbsp; &nbsp;</li>
<li>No evidence of tachyphylaxis was observed in this study over the 6-week period &nbsp;</li>
<li>Study was conducted under FDA Special Protocol Assessment and Fast-Track Designation &nbsp;</li>
</ul>

Opus Genetics; LYNX-2 Phase 3 Trial Met Primary Endpoint For Phentolamine Ophthalmic Solution 0.75% In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Management

STRO

Sutro Biopharma Appoints Greg Chow As CFO, Effective June 2, 2025

NMAX

Newsmax Expects To List On U.S. Small-Cap Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne's (formerly known as Beigene) PD-1 checkpoint inhibitor, tislelizumab. This newly activated arm of the trial will assess safety, dose optimization, and early signs of anti-tumor activity in patients with advanced solid tumors, previously treated with a checkpoint inhibitor or with tumors typically unresponsive to a checkpoint inhibitor.

INDP

Indaptus Therapeutics Doses First Patient In Phase 1b/2 Trial Expansion Of Decoy20 Combo For Advanced Solid Tumors

<h3>Gainers</h3>
<ul>
<li>Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) shares increased by 26.1% to $7.35 during Monday's pre-market session. The market value of their outstanding shares is at $3.6 billion. </li>
<li>Century Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) shares rose 18.85% to $18.41. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) stock moved upwards by 11.31% to $137.0. The market value of their outstanding shares is at $20.3 billion. </li>
<li>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) stock moved upwards by 10.74% to $121.11. The company's market cap stands at $27.9 billion. </li>
<li>Origin Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) stock moved upwards by 9.25% to $0.48. The company's market cap stands at $71.6 million. </li>
<li>Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) shares moved upwards by 9.2% to $50.88. The market value of their outstanding shares is at $5.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Projects Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) shares declined by 8.3% to $3.1 during Monday's pre-market session. The company's market cap stands at $6.3 million. </li>
<li>IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) shares decreased by 6.85% to $0.18. The market value of their outstanding shares is at $3.0 million. </li>
<li>IperionX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) stock decreased by 6.5% to $22.62. The market value of their outstanding shares is at $662.0 million. </li>
<li>Millennium Group Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIH#NASDAQ">MGIH</a>) stock fell 6.05% to $1.4. The company's market cap stands at $15.7 million. </li>
<li>Tantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) stock declined by 5.41% to $2.1. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-basic-materials-stocks/" title="www.benzinga.com/money/best-basic-materials-stocks/">www.benzinga.com/money/best-basic-materials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BSLK

CENX

MGIH

ORGN

STLD

TANH

11 Materials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Educational Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) stock increased by 53.7% to $2.09 during Monday's pre-market session. The market value of their outstanding shares is at $17.9 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock increased by 10.11% to $0.98. The company's market cap stands at $10.2 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock increased by 9.99% to $0.35. The company's market cap stands at $24.7 million. </li>
<li>United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) shares increased by 7.61% to $3.25. The market value of their outstanding shares is at $190.4 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock increased by 7.59% to $2.11. The company's market cap stands at $9.9 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares increased by 7.59% to $0.85. The market value of their outstanding shares is at $8.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) stock decreased by 28.3% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $188.1 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares declined by 21.11% to $60.51. The company's market cap stands at $42.2 million. </li>
<li>ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares fell 18.42% to $6.69. The company's market cap stands at $178.5 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock declined by 14.49% to $0.29. The company's market cap stands at $10.3 million. </li>
<li>Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) stock declined by 13.8% to $5.0. The market value of their outstanding shares is at $129.9 million. </li>
<li>High Roller Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ROLR#AMEX">ROLR</a>) shares decreased by 11.47% to $3.86. The market value of their outstanding shares is at $32.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLEU

ECDA

EDUC

LOGC

ROLR

SBET

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares moved upwards by 463.3% to $27.77 during Monday's pre-market session. The market value of their outstanding shares is at $36.8 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares increased by 62.58% to $30.81. The company's market cap stands at $1.9 billion. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 39.8% to $0.4. The company's market cap stands at $2.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock increased by 39.09% to $8.46. The market value of their outstanding shares is at $158.8 million. </li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock rose 34.95% to $40.0. The company's market cap stands at $2.6 billion. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares moved upwards by 30.9% to $35.28. The company's market cap stands at $231.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) stock declined by 24.9% to $1.46 during Monday's pre-market session. The company's market cap stands at $43.4 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock decreased by 21.98% to $0.83. The company's market cap stands at $43.2 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 19.27% to $3.96. The market value of their outstanding shares is at $2.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 16.21% to $0.87. The company's market cap stands at $7.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 12.21% to $770.0. The market value of their outstanding shares is at $10.0 billion. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 10.8% to $1.24. The company's market cap stands at $125.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

KYMR

LUCD

PSTV

RSLS

SLXN

TELO

VERA

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock moved upwards by 91.7% to $5.56 during Monday's pre-market session. The market value of their outstanding shares is at $122.3 million. </li>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) shares rose 17.43% to $1.28. The market value of their outstanding shares is at $53.9 million. </li>
<li>Arrive AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) shares increased by 14.89% to $6.71. The market value of their outstanding shares is at $201.1 million. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) stock increased by 13.11% to $1.38. The company's market cap stands at $5.1 million. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) stock moved upwards by 12.84% to $1.23. The market value of their outstanding shares is at $40.1 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) shares increased by 12.82% to $1.32. The market value of their outstanding shares is at $14.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) shares decreased by 13.1% to $0.32 during Monday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) shares decreased by 9.42% to $1.54. The market value of their outstanding shares is at $18.6 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares declined by 6.61% to $0.99. The company's market cap stands at $31.0 million. </li>
<li>Quhuo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) stock decreased by 6.56% to $1.14. The company's market cap stands at $102.2 million. </li>
<li>Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) shares fell 6.53% to $108.0. The company's market cap stands at $5.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares declined by 6.48% to $1.3. The market value of their outstanding shares is at $104.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAI

BTOC

BURU

CAPT

HKPD

HOVR

NVVE

SAIC

SPWR

WETO

12 Industrials Stocks Moving In Monday's Pre-Market Session

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul class="wp-block-list">
<li>On May 22, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split. The company's stock fell around 89% over the past five days and has a 52-week low of $3.92.</li>
<li>RSI Value: 29.4</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 8.3% to close at $3.98 on Friday.</li>
<li>Edge Stock Ratings: Value at 41.34. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/whlr"><img loading="lazy" decoding="async" width="497" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080420/image-3.png" alt="" class="wp-image-935058" style="width:410px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080420/image-3.png 497w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080420/image-3-300x110.png 300w" sizes="(max-width: 497px) 100vw, 497px" /></a></figure>
<h3 class="wp-block-heading">Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</h3>
<ul class="wp-block-list">
<li>On April 30, Office Props IT posted downbeat quarterly earnings. The company's stock fell around 40% over the past month and <a href="https://www.benzinga.com/quote/OPI">has a 52-week low</a> of $0.18.</li>
<li>RSI Value: 27.7</li>
<li>OPI Price Action: Shares of Office Properties Income Trust fell 8.1% to close at $0.19 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in OPI stock. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602"><img loading="lazy" decoding="async" width="932" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4.png" alt="" class="wp-image-935060" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4.png 932w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4-768x698.png 768w" sizes="(max-width: 932px) 100vw, 932px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

WHLR

Top 2 Real Estate Stocks That Could Surge This Quarter

Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) (the "Company"), the world's largest global temperature-controlled warehouse REIT, today announces the planned retirement of its Chief Financial Officer, Rob Crisci. The Company has started the process of identifying a successor for the position with the assistance of a leading executive search firm. Crisci will continue as CFO until a successor is in place and will remain with Lineage through a subsequent transition period.
 &nbsp;

LINE

Lineage Announces Planned Retirement Of CFO, Rob Crisci

Progress continues on the development of AVERSA Fentanyl, with the Company formalizing an exclusive product development partnership with Kindeva Drug Delivery. The formalized partnership with Kindeva Drug Delivery reflects a commitment to shared development costs in exchange for milestone payments, enabling Nutriband to advance its innovative transdermal drug delivery solutions towards regulatory approval and commercialization.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.1
1&nbsp;Health Advances Aversa Fentanyl market analysis report 2022

Earnings

NTRB

Nutriband Quarterly Reports Revenue For Q1 2025, Up 63% YOY And Announces Strategic Progress Toward NDA Filing For Abuse-Deterrent Patch Development Of AVERSA Fentanyl

Most people have heard the saying "better late than never," but it has an entirely different meaning when you're 50 years old and have no money saved up for retirement. It's a difficult situation, but it doesn't have to be the end of the world.<a href="https://www.gobankingrates.com/retirement/planning/50-with-no-retirement-savings-how-i-retired-comfortably/"> GOBankingRates</a> recently profiled an investor who got themselves out of this unenviable situation by committing to lifestyle changes, ambition, and astute planning.
Admitting you have a problem is the first step to getting out of any difficult situation. Once that's done, the next step is making a plan. That's exactly what Jennifer James did when she realized she was dangerously close to retirement age with inadequate savings. Saving money sounds like it's easy, but it can be challenging when your employment income doesn't leave you with enough discretionary funds to stash any away for a rainy day.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
That's why James' first step was improving on their $45,000 per year salary. "I knew I had to increase my income, but without a college degree, I felt stuck. I was living paycheck to paycheck just trying to get by," James told GOBankingRates. She followed the advice of several confidants by returning to school to earn her bachelor's degree. It was a struggle, but the payoff was worth it.
Getting her bachelor's degree allowed James to secure a job as an office manager and boosted her annual salary to $65,000.&nbsp; "Finally finishing my degree opened up new opportunities that changed everything," she said. "It was a struggle, but well worth the effort." By that point, James was 53, but she had the discipline to begin putting her extra income to work for her.
James told GOBankingRates that she began saving 20% of her take-home pay, a move that allowed her to stockpile investment capital and build an emergency fund. "I set up automatic transfers from my checking account to savings so I paid myself first," James said. She admitted living on such a tight budget was a challenge, but the reward made all the sacrifices worthwhile.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
According to GOBankingRates, James' next step was to make up for lost time by maximizing her 401(k) contribution, which was 15% of her pre-tax income. James was also eligible to make catch-up contributions to the 401(k) plan because she was over 50, and she exercised that option. Her employer also matched 50% of her contributions, which helped James grow her nest egg even more quickly.
&nbsp;If that wasn't enough, James also opened an<a href="https://www.benzinga.com/money/best-ira-accounts"> IRA</a> and committed to making the maximum allowable annual contribution. GOBankingRates revealed that James had saved $100,000 by the time she was 58 and felt confident enough to take the next step to wealth building: buying a house. She used her savings to put 30% down and then made bi-weekly mortgage payments before paying the loan off within eight years.
By the time James turned 60, she felt like she was ready to take the final step in building her retirement package: developing a stock portfolio. She applied the same discipline she used in getting her bachelor's degree and learned about the market. "I focused on adding money to a mix of strong<a href="https://www.benzinga.com/money/best-dividend-stocks-to-buy-and-hold"> dividend stocks</a> and low-cost index funds," James told GOBankingRates. "Dollar-cost averaging helped minimize the normal ups and downs of the market."&nbsp;&nbsp;
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
James retired from her full-time job at 65 and transitioned to a part-time job that provides her with a little extra spending money. Some might call it a miraculous turnaround, but that wouldn't be giving James enough credit. It took discipline, planning, and commitment to reach her goals, and she couldn't be happier.&nbsp; She looks back on her self-motivated transition from financial crisis to a comfortable retirement with pride.
"The key was cutting spending to maximize savings once my income increased. I'm now 68 and loving early retirement," James said. "It just goes to show, it's never too late to turn your financial life around if you focus and work a plan."
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

Personal Finance

How This Investor Went From Being 50 Years Old With No Savings To A Comfortable Retirement At 65

LMP Capital and Income Fund Board Approves 1-For-3 Rights Offering

Press Releases

WeTouch Announces First Quarter Fiscal Year 2024 Financial Results with Cash Reserves of $94.8 Million

WeTouch Technology Inc. CEO Zongyi Lian's Letter to Shareholders

Wetouch Technologies Inc. Announces $15 Million Stock Buyback Program

WeTouch Technology Inc. (NASDAQ: WETH) Announces Strategic Partnership with Leading Electronics Manufacturer to Expand into South Korean Market

WeTouch Technologies Inc. Unveils New Corporate Video and Website to Strengthen Shareholder Engagement

Comments

Wetouch Technology

Wetouch Technology (WETH) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL